Clinical trials: Cyclooxygenase 2 Inhibitors
Ovarian Cancer, Ovarian Cancer Metastatic Recurrent
Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery.
- Trial name
- OC-POP-PT (NCT06839144)
- Testing
- Propranolol (Beta-Blocker) and Etodolac (COX-2 Inhibitor)
- Where
- 2 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Tonsillectomy, Adenotonsillectomy
Celecoxib for Pediatric Adenotonsillectomy
The investigators' study will involve the administration of either placebo or celecoxib to children aged 2 to 18 years of age undergoing tonsillectomy and assessing pain relief, impact on quality of life and side effect profile.
- Conditions
- Tonsillectomy, Adenotonsillectomy, Pain, Postoperative
- Trial name
- NCT00849966
- Testing
- Celebrex suspension
- Where
- Canada
- Volunteers
- 282 people
- Sponsor
- Children's Hospital of Eastern Ontario
Female Genital Disease
Comparing Postoperative Pain Following COX-2 and Prostanoids Expression
The purpose of this study is to compare postoperative pain following COX-2 and prostanoids expression in women who underwent laparoscopic surgery for female genital disease in order to evaluate the effect of COX-2 on local…
- Trial name
- COX2RCT (NCT03391570)
- Testing
- COX-2 inhibitor, Preoperative peritoneal biopsy, Single-port laparoscopic surgery
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Duodenal Polyposis
Coxib-inhibition of Duodenal Polyp Growth in FAP
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the…
- Trial name
- NCT00844727
- Testing
- Rofecoxib
- Where
- Norway
- Volunteers
- 38 people
- Sponsor
- Oslo University Hospital
Prostate Cancer
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00073970
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center